Bis-acetatoamminedichlorocyclohexylamine platinum(IV) (BioDeep_00001029187)
代谢物信息卡片
Bis-acetatoamminedichlorocyclohexylamine platinum(IV)
化学式: C10H24Cl2N2O4Pt (501.0760894)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(=O)O.CC(=O)O.C1CCC(CC1)N.N.Cl[Pt]Cl
InChI: /q
描述信息
D000970 - Antineoplastic Agents
同义名列表
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Yao Wu, Rebecca Y Lai. Electrochemical Detection of Platinum(IV) Prodrug Satraplatin in Serum.
Analytical chemistry.
2015 Nov; 87(21):11092-7. doi:
10.1021/acs.analchem.5b03215. [PMID: 26465061] - Sarah Theiner, Christoph Kornauth, Hristo P Varbanov, Markus Galanski, Sushilla Van Schoonhoven, Petra Heffeter, Walter Berger, Alexander E Egger, Bernhard K Keppler. Tumor microenvironment in focus: LA-ICP-MS bioimaging of a preclinical tumor model upon treatment with platinum(IV)-based anticancer agents.
Metallomics : integrated biometal science.
2015 Aug; 7(8):1256-64. doi:
10.1039/c5mt00028a. [PMID: 25856224] - Srivandana Akshintala, Leigh Marcus, Katherine E Warren, Robert F Murphy, Tristan M Sissung, Anjali Srivastava, Wendy J Goodspeed, Anne Goodwin, Carmen C Brewer, Christopher Zalewski, Kelly A King, AeRang Kim, William D Figg, Brigitte C Widemann. Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors.
Pediatric blood & cancer.
2015 Apr; 62(4):603-10. doi:
10.1002/pbc.25344. [PMID: 25556988] - Sarah Theiner, Hristo P Varbanov, Markus Galanski, Alexander E Egger, Walter Berger, Petra Heffeter, Bernhard K Keppler. Comparative in vitro and in vivo pharmacological investigation of platinum(IV) complexes as novel anticancer drug candidates for oral application.
Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry.
2015 Jan; 20(1):89-99. doi:
10.1007/s00775-014-1214-6. [PMID: 25413442] - Enas M Ahmed, Shohda A EL-Maraghy, Zakaria A Teleb, Amira A Shaheen. Pretreatment with turmeric modulates the inhibitory influence of cisplatin and paclitaxel on CYP2E1 and CYP3A1/2 in isolated rat hepatic microsomes.
Chemico-biological interactions.
2014 Sep; 220(?):25-32. doi:
10.1016/j.cbi.2014.05.007. [PMID: 24882083] - M D Galsky, L H Camacho, E G Chiorean, D Mulkerin, D S Hong, W K Oh, D F Bajorin. Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology.
2012 Apr; 23(4):1037-44. doi:
10.1093/annonc/mdr358. [PMID: 21828377] - Leigh Marcus, Robert Murphy, Elizabeth Fox, Cynthia McCully, Raphael Cruz, Katherine E Warren, Thorsten Meyer, Edward McNiff, Frank M Balis, Brigitte C Widemann. The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates.
Cancer chemotherapy and pharmacology.
2012 Jan; 69(1):247-52. doi:
10.1007/s00280-011-1659-z. [PMID: 21706317] - K A Selting, X Wang, D L Gustafson, C J Henry, J A Villamil, D L McCaw, D Tate, M Beittenmiller, C Garnett, J D Robertson. Evaluation of satraplatin in dogs with spontaneously occurring malignant tumors.
Journal of veterinary internal medicine.
2011 Jul; 25(4):909-15. doi:
10.1111/j.1939-1676.2011.0727.x. [PMID: 21564292] - Petr Sova, Adolf Mistr, Ales Kroutil, Martin Semerád, Hana Chlubnová, Veronika Hrusková, Jirina Chládková, Jaroslav Chládek. A comparative study of pharmacokinetics, urinary excretion and tissue distribution of platinum in rats following a single-dose oral administration of two platinum(IV) complexes LA-12 (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV) and satraplatin (OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum(IV).
Cancer chemotherapy and pharmacology.
2011 Jun; 67(6):1247-56. doi:
10.1007/s00280-010-1411-0. [PMID: 20697713] - Alejandro D Ricart, John Sarantopoulos, Emiliano Calvo, Quincy S Chu, Douglas Greene, Faith E Nathan, Michael E Petrone, Anthony W Tolcher, Kyriakos P Papadopoulos. Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2009 Jun; 15(11):3866-71. doi:
10.1158/1078-0432.ccr-08-2373. [PMID: 19458055] - Deanna N Bell, Johnson J Liu, Malcolm D Tingle, Benno Rattel, Thorsten Ulf Meyer, Mark J McKeage. Comparative protein binding, stability and degradation of satraplatin, JM118 and cisplatin in human plasma in vitro.
Clinical and experimental pharmacology & physiology.
2008 Dec; 35(12):1440-6. doi:
10.1111/j.1440-1681.2008.05017.x. [PMID: 18671714] - Goli Samimi, Stephen B Howell. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
Cancer chemotherapy and pharmacology.
2006 Jun; 57(6):781-8. doi:
10.1007/s00280-005-0121-5. [PMID: 16170571] - Sylvie Vouillamoz-Lorenz, Thierry Buclin, Ferdy Lejeune, Jean Bauer, Serge Leyvraz, Laurent Arthur Decosterd. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
Anticancer research.
2003 May; 23(3C):2757-65. doi:
NULL. [PMID: 12926110] - Jocelyn L Carr, Malcolm D Tingle, Mark J McKeage. Rapid biotransformation of satraplatin by human red blood cells in vitro.
Cancer chemotherapy and pharmacology.
2002 Jul; 50(1):9-15. doi:
10.1007/s00280-002-0462-2. [PMID: 12111106] - S Vouillamoz-Lorenz, J Bauer, F Lejeune, L A Decosterd. Validation of an AAS method for the determination of platinum in biological fluids from patients receiving the oral platinum derivative JM216.
Journal of pharmaceutical and biomedical analysis.
2001 Jun; 25(3-4):465-75. doi:
10.1016/s0731-7085(00)00508-2. [PMID: 11377026] - T Kurata, T Tamura, Y Sasaki, H Fujii, S Negoro, M Fukuoka, N Saijo. Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study.
Japanese journal of clinical oncology.
2000 Sep; 30(9):377-84. doi:
10.1093/jjco/hyd102. [PMID: 11095134] - B Xing, H Zhu, Y Wang, W Tang. Binding properties of an orally active platinum anti-tumor drug JM216 with metallothionein in vivo.
Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine.
2000 Sep; 13(3):203-8. doi:
10.1023/a:1009236927190. [PMID: 11127891] - L R Kelland. An update on satraplatin: the first orally available platinum anticancer drug.
Expert opinion on investigational drugs.
2000 Jun; 9(6):1373-82. doi:
10.1517/13543784.9.6.1373. [PMID: 11060749] - E Fokkema, E G de Vries, S Meijer, H J Groen. Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patients.
Cancer chemotherapy and pharmacology.
2000; 45(1):89-92. doi:
10.1007/pl00006749. [PMID: 10647508] - E M Bengtson, J R Rigas. New oral chemotherapeutic agents for lung cancer.
Drugs.
1999; 58 Suppl 3(?):57-69. doi:
10.2165/00003495-199958003-00009. [PMID: 10711843] - P Beale, F Raynaud, J Hanwell, C Berry, S Moore, D Odell, I Judson. Phase I study of oral JM216 given twice daily.
Cancer chemotherapy and pharmacology.
1998; 42(2):142-8. doi:
10.1007/s002800050797. [PMID: 9654114] - M J McKeage, F Raynaud, J Ward, C Berry, D O'Dell, L R Kelland, B Murrer, P Santabárabara, K R Harrap, I R Judson. Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
1997 Jul; 15(7):2691-700. doi:
10.1200/jco.1997.15.7.2691. [PMID: 9215842] - F I Raynaud, D E Odell, L R Kelland. Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels.
British journal of cancer.
1996 Aug; 74(3):380-6. doi:
10.1038/bjc.1996.369. [PMID: 8695352] - F I Raynaud, F E Boxall, P Goddard, C F Barnard, B A Murrer, L R Kelland. Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products.
Anticancer research.
1996 Jul; 16(4A):1857-62. doi:
. [PMID: 8712713] - F I Raynaud, P Mistry, A Donaghue, G K Poon, L R Kelland, C F Barnard, B A Murrer, K R Harrap. Biotransformation of the platinum drug JM216 following oral administration to cancer patients.
Cancer chemotherapy and pharmacology.
1996; 38(2):155-62. doi:
10.1007/s002800050464. [PMID: 8616906] - P I Bates, H L Sharma, B A Murrer, C A McAuliffe. The tissue distribution in BALB/c mice of C-14-labeled JM216, an orally active platinum antitumour compound.
Cancer chemotherapy and pharmacology.
1996; 39(1-2):170-5. doi:
10.1007/s002800050555. [PMID: 8995517] - G K Poon, P Mistry, F I Raynaud, K R Harrap, B A Murrer, C F Barnard. Determination of metabolites of a novel platinum anticancer drug JM216 in human plasma ultrafiltrates.
Journal of pharmaceutical and biomedical analysis.
1995 Nov; 13(12):1493-8. doi:
10.1016/0731-7085(95)01571-x. [PMID: 8788134] - G K Poon, F I Raynaud, P Mistry, D E Odell, L R Kelland, K R Harrap, C F Barnard, B A Murrer. Metabolic studies of an orally active platinum anticancer drug by liquid chromatography-electrospray ionization mass spectrometry.
Journal of chromatography. A.
1995 Sep; 712(1):61-6. doi:
10.1016/0021-9673(95)00288-x. [PMID: 8556156] - S Y Sharp, P M Rogers, L R Kelland. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
Clinical cancer research : an official journal of the American Association for Cancer Research.
1995 Sep; 1(9):981-9. doi:
NULL. [PMID: 9816070] - M J McKeage, P Mistry, J Ward, F E Boxall, S Loh, C O'Neill, P Ellis, L R Kelland, S E Morgan, B Murrer. A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration.
Cancer chemotherapy and pharmacology.
1995; 36(6):451-8. doi:
10.1007/bf00685793. [PMID: 7554035] - M J McKeage, L R Kelland, F E Boxall, M R Valenti, M Jones, P M Goddard, J Gwynne, K R Harrap. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.
Cancer research.
1994 Aug; 54(15):4118-22. doi:
NULL. [PMID: 8033145]